Orbis Allan Gray LTD Crispr Therapeutics Ag Transaction History
Orbis Allan Gray LTD
- $14.8 Billion
- Q4 2024
A detailed history of Orbis Allan Gray LTD transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Orbis Allan Gray LTD holds 1,476,119 shares of CRSP stock, worth $73.4 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
1,476,119Holding current value
$73.4 Million% of portfolio
0.39%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
60.3MCall Options Held
1.26MPut Options Held
1.81M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$446 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$435 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$138 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$137 Million0.07% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$137 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.88B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....